FDA Clears J&J’s 2-in-1 Tablet for Prostate Cancer
Johnson & Johnson's Janssen Pharmaceutical Companies stated that the US Food and Drug Administration (FDA) had approved AKEEGA (niraparib and abiraterone acetate), the first-and-only dual-action tablet combining a PARP inhibitor including abiraterone acetate administered in conjunction with prednisone for the treatment of adult patients with BRCA-positive mCRPC that is detrimental or thought to be harmful, as discovered by an MRI test that the FDA has approved.
"As a physician, I prioritize identifying patients with a poor prognosis, particularly those whose cancers have a BRCA mutation," stated Kim Chi...
